Navigation Links
Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare and Baird Global Healthcare Conferences
Date:9/7/2010

SAN DIEGO, Sept. 7, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Morgan Stanley Global Healthcare Conference on Monday, September 13, 2010 at 10:55 a.m. ET / 7:55 a.m. PT in New York, and at the Baird Global Healthcare Conference on Tuesday, September 14, 2010 at 11:30 a.m. ET / 8:30 a.m. PT in New York. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview at the Morgan Stanley conference. Alex Casdin, vice president, finance of Amylin, will provide a corporate overview at the Baird conference.

The presentations will be webcast live through the "Investors" section of Amylin's corporate Web site at www.amylin.com, and the recordings will be made available on the Web site following the events. To access the live webcasts, please log on to Amylin's Web site approximately fifteen minutes prior to the presentations to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amylin Pharmaceuticals to Present at the 2010 Jefferies Global Life Sciences Conference
2. Amylin Pharmaceuticals to Present at the 2010 Citi Investment Research Global Healthcare Conference
3. Amylin Pharmaceuticals to Present at the Deutsche Bank 35th Annual Healthcare Conference
4. Amylin Pharmaceuticals to Webcast Third Quarter Results
5. Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009
6. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
7. Amylin Pharmaceuticals Board of Directors Elects Paulo F. Costa Chairman of the Board
8. Amylin Pharmaceuticals to Webcast Second Quarter Results
9. Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
10. Amylin Pharmaceuticals to Present at Piper Jaffray Europe Conference
11. Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... , January 20, 2017 ... cancer is one of leading causes of death worldwide. ... Although the number of cancer related deaths increased gradually ... Rising in incidence rate of various cancers continues to ... a research report by Global Market Insights, Inc. cancer ...
(Date:1/19/2017)... Future has a half cooked research report on Global Liquid Biopsy ... expected to reach USD 450 Million by the end of the ... ... as a swiftly growing market and expected that the market will ... has been a tremendous growth in the prevalence of cancer disease ...
(Date:1/19/2017)... 19, 2017 Research and Markets ... has announced the addition of the ... Forecast to 2025" report to their offering. ... The report provides a detailed analysis on current and future market trends ... using estimated market values as the base numbers Key ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, 2017 ... Inc., a privately-held immunotherapeutics company targeting infectious diseases, ... for the merger of PharmAthene and Altimmune in ... Venture Fund, HealthCap, Truffle Capital and Redmont Capital. ... diversified immunotherapeutics company with four clinical stage and ...
Breaking Biology Technology:
(Date:1/18/2017)... 18, 2017  In vitro diagnostic (IVD) companies were ... acquisitions (M&A), and Kalorama Information expects that trend to ... been shifting. Generally, uncertainty in reimbursement and healthcare reform ... has changed the acquisitions landscape. Instead of looking to ... buying partners outside of their home country and also ...
(Date:1/12/2017)... 12, 2017  Trovagene, Inc. (NASDAQ: TROV ... today announced that it has signed agreements with seven ... the Middle East for commercialization ... the first wave of international distribution agreements for Trovagene,s ... samples. The initial partners will introduce Trovagene,s ...
(Date:1/11/2017)... Iowa , Jan. 11, 2017 Intoxalock, ... first with the release of its patent-pending calibration device. ... and reliably perform calibrations, securely upload data logs and ... for the customer. "Fighting drunk driving through ... for the public at large, but also for the ...
Breaking Biology News(10 mins):